A pair of major media outlets that actively cover the cannabis industry recently lauded the efforts of the Council for Cannabis Regulation (CFCR) for the role the non-profit hopes to play in support of a nationwide effort to encourage the US Food and Drug Administration (FDAs) to expand its discretion on enforcement and issue specific policy guidelines relative to federal cannabinoid hemp regulations.
Benzinga, a daily online platform that provides articles on cannabis and hemp stocks and news about CBD, psychedelics, business and culture, praised CFCR for its 26-page response to a Federal Request for Information (RFI) seeking input from qualified, interested industry players. In its submission, CFCR described a marketplace that has metamorphosized significantly since the passage of the 2018 Farm Bill.
Benzinga writes: This bill, while an important step forward, opened Pandora’s box, allowing some unscrupulous businesses to peddle poorly regulated CBD products. As a result, consumers are confronted with a bewildering assortment of options, some of which may not be safe. CFCR is candid in its depiction: a terrain marred by “bad actors” and “false labeling,” where consumers are left clueless about which products to trust. Consumers have no ability to differentiate between a safe and unsafe product.”
Cannabis Business Times acknowledged the association’s push to encourage the FDA to act swiftly to do its part to reform the marketplace, an action that is desperately needed to both improve the state of the cannabis industry and advance consumer protection.
Marijuana Moment, another influential online outlet, noted CFCR’s support for an industry-wide push to the FDA to adopt universal labeling of cannabis and CBD products.
For CFCR Founder and Board Chair Sheri Orlowitz, the coverage certainly adds credibility to the organization’s mission. “I’m very excited about the position we are suggestion and I’m grateful that a few extremely influential media outlets also recognize the merits,” she said. “On the back end of this, we’re going to go to Congress and explain to them what FDA has been doing with regards to regulation and also what more they could be doing to regulate.”
